Tipsheet
What matters at India’s listed companies

Anupam Rasayan buys 43% of Bliss GVS Pharma in ₹2,198 crore deal

Anupam Rasayan will take control of Bliss GVS Pharma after signing a share purchase agreement to acquire a 43.3% stake at ₹299 per share.


Mkt cap₹3,177 cr
P/E24.61×
ROE8.03%
Debt / eq.0.07
Div yld0.33%
₹2,198 cr Total transaction value including the mandatory open offer.

What's new

  • Anupam Rasayan is acquiring a 43.3% stake in Bliss GVS Pharma for ₹1,370 crore.
  • A mandatory open offer for an additional 26% of equity at ₹299 per share follows.
  • The deal marks a change of control, with Anupam Rasayan becoming the new promoter.

Why this matters

This acquisition is a major shift for Bliss GVS, especially after the company previously denied takeover speculation. The deal forces a total change in governance and ownership structure, with the current promoters moving to the public category.

What we're watching

  • Regulatory approvals required to finalize the change of control.
  • Any potential shift in strategic direction under the new promoter.
  • The response of public shareholders to the mandatory open offer.

The full read

Anupam Rasayan India Ltd. is taking control of Bliss GVS Pharma. It has signed a share purchase agreement to acquire a 43.3% stake from existing promoters and select public shareholders at ₹299 per share, a transaction worth ₹1,370 crore. This move triggers a mandatory open offer for an additional 26% of the equity, valued at ₹829 crore. The total deal size reaches ₹2,198 crore, which represents roughly 69% of Bliss GVS's current market capitalization of ₹3,176 crore. The acquisition marks a definitive change of control, with Anupam Rasayan stepping in as the new promoter while the current promoter group shifts to public shareholder status. This development is a sharp reversal from recent company statements that denied takeover rumors. With the open offer lacking any minimum acceptance threshold, the path is clear for a total overhaul of the company's governance and strategic direction.

Questions answered

What is the price offered to public shareholders?
The mandatory open offer is priced at ₹299 per share, matching the price paid to the exiting promoters.
How much of the company is Anupam Rasayan acquiring?
Anupam Rasayan is buying a 43.3% stake via a share purchase agreement and is offering to buy an additional 26% through the mandatory open offer.
What happens to the existing promoters?
The existing promoter group will be reclassified as public shareholders once the acquisition and change of control are complete.
Is the open offer conditional?
No, the open offer is not conditional on any minimum acceptance level.
Mentioned: Anupam Rasayan India Ltd. · Bliss GVS Pharma Ltd. · ₹299 per share
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.